Cargando…

Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats

Insulin is a vital part of diabetes treatment, whereas glucagon is primarily used to treat insulin-induced hypoglycemia. However, glucagon is suggested to have a central role in the regulation of body weight, which would be beneficial for diabetic patients. Since the glucagon effect on blood glucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Christina, Porsgaard, Trine, Thomsen, Maria, Rosenkilde, Mette Marie, Roed, Nikolaj Kulahin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860770/
https://www.ncbi.nlm.nih.gov/pubmed/29558502
http://dx.doi.org/10.1371/journal.pone.0194468
_version_ 1783307997588488192
author Pedersen, Christina
Porsgaard, Trine
Thomsen, Maria
Rosenkilde, Mette Marie
Roed, Nikolaj Kulahin
author_facet Pedersen, Christina
Porsgaard, Trine
Thomsen, Maria
Rosenkilde, Mette Marie
Roed, Nikolaj Kulahin
author_sort Pedersen, Christina
collection PubMed
description Insulin is a vital part of diabetes treatment, whereas glucagon is primarily used to treat insulin-induced hypoglycemia. However, glucagon is suggested to have a central role in the regulation of body weight, which would be beneficial for diabetic patients. Since the glucagon effect on blood glucose is known to be transient, it is relevant to investigate the pharmacodynamics of glucagon after repeated dosing. In the present study, we used telemetry to continuously measure blood glucose in streptozotocin induced diabetic Sprague-Dawley rats. This allowed for a more detailed analysis of glucose regulation compared to intermittent blood sampling. In particular, we evaluated the blood glucose-lowering effect of different insulin doses alone, and in combination with a long acting glucagon analog (LAG). We showed how the effect of the LAG accumulated and persisted over time. Furthermore, we found that addition of the LAG decreased body weight without affecting food intake. In a subsequent study, we focused on the glucagon effect on body weight and food intake during equal glycemic control. In order to obtain comparable maximum blood glucose lowering effect to insulin alone, the insulin dose had to be increased four times in combination with 1 nmol/kg of the LAG. In this set-up the LAG prevented further increase in body weight despite the four times higher insulin-dose. However, the body composition was changed. The insulin group increased both lean and fat mass, whereas the group receiving four times insulin in combination with the LAG only significantly increased the fat mass. No differences were observed in food intake, suggesting a direct effect on energy expenditure by glucagon. Surprisingly, we observed decreased levels of FGF21 in plasma compared to insulin treatment alone. With the combination of insulin and the LAG the blood glucose-lowering effect of insulin was prolonged, which could potentially be beneficial in diabetes treatment.
format Online
Article
Text
id pubmed-5860770
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58607702018-03-28 Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats Pedersen, Christina Porsgaard, Trine Thomsen, Maria Rosenkilde, Mette Marie Roed, Nikolaj Kulahin PLoS One Research Article Insulin is a vital part of diabetes treatment, whereas glucagon is primarily used to treat insulin-induced hypoglycemia. However, glucagon is suggested to have a central role in the regulation of body weight, which would be beneficial for diabetic patients. Since the glucagon effect on blood glucose is known to be transient, it is relevant to investigate the pharmacodynamics of glucagon after repeated dosing. In the present study, we used telemetry to continuously measure blood glucose in streptozotocin induced diabetic Sprague-Dawley rats. This allowed for a more detailed analysis of glucose regulation compared to intermittent blood sampling. In particular, we evaluated the blood glucose-lowering effect of different insulin doses alone, and in combination with a long acting glucagon analog (LAG). We showed how the effect of the LAG accumulated and persisted over time. Furthermore, we found that addition of the LAG decreased body weight without affecting food intake. In a subsequent study, we focused on the glucagon effect on body weight and food intake during equal glycemic control. In order to obtain comparable maximum blood glucose lowering effect to insulin alone, the insulin dose had to be increased four times in combination with 1 nmol/kg of the LAG. In this set-up the LAG prevented further increase in body weight despite the four times higher insulin-dose. However, the body composition was changed. The insulin group increased both lean and fat mass, whereas the group receiving four times insulin in combination with the LAG only significantly increased the fat mass. No differences were observed in food intake, suggesting a direct effect on energy expenditure by glucagon. Surprisingly, we observed decreased levels of FGF21 in plasma compared to insulin treatment alone. With the combination of insulin and the LAG the blood glucose-lowering effect of insulin was prolonged, which could potentially be beneficial in diabetes treatment. Public Library of Science 2018-03-20 /pmc/articles/PMC5860770/ /pubmed/29558502 http://dx.doi.org/10.1371/journal.pone.0194468 Text en © 2018 Pedersen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Pedersen, Christina
Porsgaard, Trine
Thomsen, Maria
Rosenkilde, Mette Marie
Roed, Nikolaj Kulahin
Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats
title Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats
title_full Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats
title_fullStr Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats
title_full_unstemmed Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats
title_short Sustained effect of glucagon on body weight and blood glucose: Assessed by continuous glucose monitoring in diabetic rats
title_sort sustained effect of glucagon on body weight and blood glucose: assessed by continuous glucose monitoring in diabetic rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860770/
https://www.ncbi.nlm.nih.gov/pubmed/29558502
http://dx.doi.org/10.1371/journal.pone.0194468
work_keys_str_mv AT pedersenchristina sustainedeffectofglucagononbodyweightandbloodglucoseassessedbycontinuousglucosemonitoringindiabeticrats
AT porsgaardtrine sustainedeffectofglucagononbodyweightandbloodglucoseassessedbycontinuousglucosemonitoringindiabeticrats
AT thomsenmaria sustainedeffectofglucagononbodyweightandbloodglucoseassessedbycontinuousglucosemonitoringindiabeticrats
AT rosenkildemettemarie sustainedeffectofglucagononbodyweightandbloodglucoseassessedbycontinuousglucosemonitoringindiabeticrats
AT roednikolajkulahin sustainedeffectofglucagononbodyweightandbloodglucoseassessedbycontinuousglucosemonitoringindiabeticrats